Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hee Yeon | - |
dc.contributor.author | Hong, Ji Hyung | - |
dc.contributor.author | Byun, Jae Ho | - |
dc.contributor.author | Kim, Hee-Jun | - |
dc.contributor.author | Baek, Sun Kyung | - |
dc.contributor.author | Kim, Jin Young | - |
dc.contributor.author | Kim, Ki Hyang | - |
dc.contributor.author | Yun, Jina | - |
dc.contributor.author | Kim, Jung A. | - |
dc.contributor.author | Park, Kwonoh | - |
dc.contributor.author | Lee, Hyo Jin | - |
dc.contributor.author | Lee, Jung Lim | - |
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Kim, Il Hwan | - |
dc.contributor.author | Bae, Woo Kyun | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Sun, Der-Sheng | - |
dc.contributor.author | Lee, Suee | - |
dc.contributor.author | Lee, Min-Young | - |
dc.contributor.author | Lee, Guk Jin | - |
dc.contributor.author | Hong, Sook Hee | - |
dc.contributor.author | Jung, Yun Hwa | - |
dc.contributor.author | An, Ho Jung | - |
dc.date.available | 2020-04-10T02:22:40Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.issn | 2005-9256 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/38195 | - |
dc.description.abstract | Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease <= 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.title | Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea | - |
dc.type | Article | - |
dc.identifier.doi | 10.4143/crt.2019.292 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.52, no.1, pp 277 - 283 | - |
dc.identifier.kciid | ART002549163 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000507387500024 | - |
dc.identifier.scopusid | 2-s2.0-85077934315 | - |
dc.citation.endPage | 283 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 277 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 52 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Ovarian epithelial carcinoma | - |
dc.subject.keywordAuthor | Clear cell adenocarcinoma | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordAuthor | Adjuvant chemotherapy | - |
dc.subject.keywordPlus | PROGRESSION-FREE SURVIVAL | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | ARID1A EXPRESSION | - |
dc.subject.keywordPlus | ENDOMETRIOSIS | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | COHORT | - |
dc.subject.keywordPlus | EVENT | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.